AGOBYL LIQUIDE 300 MG / 10 ML
PEPTONE : 300 MG / 10 ML MAGNESIUM SULFATE : 1.37 G / 10 ML · DIN 00086428 · DESBERGERS LTÉE, DIVISION OF TECHNILAB INC.
Health Canada status: CANCELLED POST MARKET
What is AGOBYL LIQUIDE?
AGOBYL LIQUIDE 300 MG / 10 ML contains PEPTONE : 300 MG / 10 ML MAGNESIUM SULFATE : 1.37 G / 10 ML. It is listed in the Health Canada Drug Product Database under DIN 00086428, held by DESBERGERS LTÉE, DIVISION OF TECHNILAB INC., supplied as LIQUID for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 06-Sep-2000. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00086428 |
|---|---|
| Brand name | AGOBYL LIQUIDE |
| Generic / active ingredient | PEPTONE : 300 MG / 10 ML MAGNESIUM SULFATE : 1.37 G / 10 ML |
| Manufacturer | DESBERGERS LTÉE, DIVISION OF TECHNILAB INC. |
| Strength | 300 MG / 10 ML |
| Dosage form | LIQUID |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A06AD54 MAGNESIUM SULPHATE, COMBINATIONS |
| AHFS class | 56:12.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 06-Sep-2000 |
| Original market date | 1951-12-31 00:00:00 |
Is MAGNESIUM SULPHATE, COMBINATIONS in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code A06AD54 MAGNESIUM SULPHATE, COMBINATIONS. 0 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AGOBYL GRANULE | 40 % | POWDER | DESBERGERS LTÉE, DIVISION OF TECHNILAB INC. | CANCELLED POST MARKET | DIN 00303496 |
| FORMULE 1705 - LIQ | 1.56 MG | LIQUID | BIO VITA | CANCELLED POST MARKET | DIN 02201968 |
Who else supplies MAGNESIUM SULPHATE, COMBINATIONS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MAGNESIUM SULPHATE, COMBINATIONS appears in 235 registered pack listings across 12 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.